High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI

被引：0
|
作者：
De Caterina, R. [1 ]
Lopez Sendon, J. L. [2 ]
Mehta, S. [3 ]
Opolski, G. [4 ]
Oldgren, J. [5 ]
Steg, P. G. [6 ]
Hohnloser, S. [7 ]
Lip, G. Y. H. [8 ]
Kimura, T. [9 ]
Nordaby, M. [10 ]
Kleine, E. [10 ]
Ten Berg, J. M. [11 ]
Bhatt, D. L. [12 ]
Cannon, C. [13 ]
机构：
[1] Univ G dAnnunzio, Chieti, Italy
[2] Univ Hosp La Paz, Madrid, Spain
[3] McMaster Univ, Hamilton, ON, Canada
[4] Med Univ Warsaw, Warsaw, Poland
[5] Uppsala Univ, Uppsala, Sweden
[6] Hosp Bichat Claude Bernard, Paris, France
[7] Goethe Univ Frankfurt, Frankfurt, Germany
[8] Birmingham City Hosp, Birmingham, W Midlands, England
[9] Kyoto Univ, Kyoto, Japan
[10] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[11] St Antonius Hosp, Nieuwegein, Netherlands
[12] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[13] Baim Inst Clin Res, Boston, MA USA
来源：
EUROPEAN HEART JOURNAL | 2018年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P2298
引用
收藏
页码：458 / 458
页数：1
相关论文
共 50 条
  • [21] Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
    Oldgren, Jonas
    Steg, Philippe Gabriel
    Hohnloser, Stefan H.
    Lip, Gregory Y. H.
    Kimura, Takeshi
    Nordaby, Matias
    Brueckmann, Martina
    Kleine, Eva
    ten Berg, Jurrien M.
    Bhatt, Deepak L.
    Cannon, Christopher P.
    EUROPEAN HEART JOURNAL, 2019, 40 (19) : 1553 - +
  • [22] Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied, D.
    Brachmann, J.
    Darius, H.
    Frey, N.
    Katus, H. A.
    Rottbauer, W.
    Schaefer, A.
    Thiele, H.
    Bode, C.
    Zeymer, Uwe
    CLINICAL RESEARCH IN CARDIOLOGY, 2018, 107 (07) : 533 - 538
  • [23] Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    D. Duerschmied
    J. Brachmann
    H. Darius
    N. Frey
    H. A. Katus
    W. Rottbauer
    A. Schäfer
    H. Thiele
    C. Bode
    Uwe Zeymer
    Clinical Research in Cardiology, 2018, 107 : 533 - 538
  • [24] A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial
    Zwart, Bastiaan
    Bor, Willem Lambertus
    de Veer, Anne Johanna Wilhelmina Maria
    Mahmoodi, Bakhtawar Khan
    Kelder, Johannes Christiaan
    Lip, Gregory Y. H.
    Bhatt, Deepak L.
    Cannon, Christopher P.
    ten Berg, Jurrien Maria
    EUROINTERVENTION, 2022, 18 (04) : E292 - +
  • [25] Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial
    Nicolau, Jose C.
    Bhatt, Deepak L.
    Hohnloser, Stefan H.
    Kimura, Takeshi
    Lip, Gregory Y. H.
    Miede, Corinna
    Nordaby, Matias
    Oldgren, Jonas
    Steg, Philippe Gabriel
    ten Berg, Jurrien M.
    Godoy, Lucas C.
    Cannon, Christopher P.
    DRUGS, 2020, 80 (10) : 995 - 1005
  • [26] Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial
    José C. Nicolau
    Deepak L. Bhatt
    Stefan H. Hohnloser
    Takeshi Kimura
    Gregory Y. H. Lip
    Corinna Miede
    Matias Nordaby
    Jonas Oldgren
    Philippe Gabriel Steg
    Jurriën M. ten Berg
    Lucas C. Godoy
    Christopher P. Cannon
    Drugs, 2020, 80 : 995 - 1005
  • [27] Dual antithrombotic therapy with oral anticoagulant and P2Y12 inhibitors in patients with atrial fibrillation after percutaneous coronary intervention
    Kitahara, Hideki
    Yamashita, Daichi
    Sato, Takanori
    Suzuki, Sakuramaru
    Hiraga, Takashi
    Yamazaki, Tatsuro
    Matsumoto, Tadahiro
    Kobayashi, Takahiro
    Ohno, Yuji
    Harada, Junya
    Fukushima, Kenichi
    Asano, Tatsuhiko
    Ishio, Naoki
    Uchiyama, Raita
    Miyahara, Hirofumi
    Okino, Shinichi
    Sano, Masanori
    Kuriyama, Nehiro
    Yamamoto, Masashi
    Sakamoto, Naoya
    Kanda, Junji
    Kobayashi, Yoshio
    JOURNAL OF CARDIOLOGY, 2023, 82 (03) : 207 - 214
  • [28] Comparison of clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing PCI
    Kook, H.
    Yu, C. W.
    Jeong, H. S.
    Jang, D. H.
    Lee, S. H.
    Joo, H. J.
    Park, J. H.
    Hong, S. J.
    Lim, D. S.
    Shim, W. J.
    Kim, J. S.
    Lee, H. J.
    Kang, W. C.
    EUROPEAN HEART JOURNAL, 2018, 39 : 333 - 333
  • [29] Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial -
    Ako, Junya
    Okumura, Ken
    Nakao, Koichi
    Kozuma, Ken
    Morino, Yoshihiro
    Okazaki, Kotaro
    Fukaya, Taku
    Kimura, Takeshi
    CIRCULATION JOURNAL, 2019, 83 (02) : 327 - +
  • [30] Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI
    Ali Ayoub
    Karnika Ayinapudi
    Ahmed Al-Ogaili
    Muhammad Siyab Panhwar
    Wael Dakkak
    Thierry LeJemtel
    American Journal of Cardiovascular Drugs, 2021, 21 : 153 - 163
12345